PBLS Parabilis Medicines, Inc.
Price Chart
Executive Summary
Parabilis Medicines' S-1 registration statement (File No. 333-296032) became effective on June 9, 2026, clearing the way for the company's IPO of 33,333,334 shares at a $17.00-$19.00 price range. The offering includes a concurrent $75.0M private placement by Regeneron at 90% of the IPO price, and proceeds will fund clinical development of lead candidate zolucatetide in desmoid tumors, advance the preclinical pipeline, and extend cash runway into H2 2029.
Actionable Insight
IPO pricing is expected within 1-2 days. The $75.0M Regeneron anchor investment signals strong institutional backing. Monitor pricing announcement and first-day trading for liquidity and valuation read-through.
Key Facts
- IPO registration declared effective on June 9, 2026
- Offering of 33,333,334 shares at $17.00-$19.00 per share
- Regeneron to invest $75.0M in private placement at 90% of IPO price
- Proceeds to fund zolucatetide clinical development and preclinical pipeline
- Cash runway extended into H2 2029
Financial Impact
Up to $633.3M gross IPO proceeds (33,333,334 shares × $19.00 midpoint) plus $75.0M Regeneron private placement, totaling up to ~$708.3M in new capital
Risk Factors
- Clinical-stage biotech with no approved products; zolucatetide development risk
- Dilution from 33.3M new shares; post-IPO share count will increase significantly
- Market conditions could impact IPO pricing and aftermarket performance
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001929 |
| Document: 9999999995-26-001929-index.html | 9999999995-26-001929 |
| Document: 9999999995-26-001929.txt | 9999999995-26-001929 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
3d ago
|
8-K
| $30.30 awaiting T+20 | awaiting T+20 | — | $27.26 (−10.03%) |
|
Jun 10, 2026
4d ago
|
424B4
| $32.16 awaiting T+20 | awaiting T+20 | — | $27.26 (−15.24%) |
|
Jun 10, 2026
5d ago
|
EFFECT
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
3
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
|
Jun 10, 2026
5d ago
|
Press Release
| $33.35 awaiting T+20 | awaiting T+20 | — | $27.26 (−18.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access